N/A N=44 Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Number of Polyps — 18.6; 22.6 Number of Polyps
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=171 Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Number of Subjects With Any FAP-related Event. — 18; 23; 22; 2 Participants — p=0.1210
Phase 2 N=92 A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Adenomatous Polyposis Coli
Primary: Change in Duodenal Polyp Burden From Baseline to 6 Months — -8.5; 8.0 mm — p=<0.001
Phase 2 N=44 Curcumin in Treating Patients With Familial Adenomatous Polyposis
Familial Adenomatous Polyposis
Primary: Polyp Number — 22.6; 18.6 polyps — p=0.58
Phase 2 N=46 Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Attenuated Familial Adenomatous Polyposis · Familial Adenomatous Polyposis
Primary: Mean Percent Change in Duodenal Polyp Burden — -29.6 percent change in Duodenal Polyp Burden
Phase 2 N=4 Sirolimus and Familial Adenomatous Polyposis (FAP)
Adenomatous Polyposis Coli
Primary: Change in Marked Polyp Size — 16; 4; 0 Size of marked polyps
Phase 2 N=112 Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
Colorectal Cancer · Familial Adenomatous Polyposis
Primary: Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum — -1; -11; -1; -13 percentage change in polyp count
Phase 3 N=58 Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
Familial Adenomatous Polyposis Coli · FAP
Primary: Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum. — -0.5; 0.5 Change from baseline number of polyps. — p=0.005
Phase 2 N=47 Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Familial Adenomatous Polyposis
Primary: 13-HODE Colonic Tissue Levels — 14.56; 18.83; 23.02; 20.03 ng/mg tissue protein
Phase 1 N=24 Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Change From Baseline to End of Study in Number of Rectal Polyps — -5.4; -1.6; -3.5 polyps — p=0.065
Phase 2 N=25 BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Pancreatic Cancer
Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants
Phase 2 N=17 Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Desmoid Tumors · Aggressive Fibromatosis
Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants
Phase 3 N=243 Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
Colorectal Neoplasms · Trifluridine and Tipiracil · Circulating Tumor DNA
Primary: Disease-free Survival 1 (DFS1) — 9.30; 5.55 Months
Phase 3 N=128 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Familial Amyloid Polyneuropathy
Primary: Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18 — 45.3; 29.5 percentage of participants
N/A N=40 Hybrid APC Assisted EMR for Large Colon Polyps
Colon Polyp · Colon Adenoma · Colon Cancer
Primary: Percentage of Participants Having Complete Resection — 40 Participants
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Phase 2 N=28 FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Locally Advanced Pancreatic Cancer · Pancreatic Cancer
Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants
N/A N=1,000 ATTENUATE (rAdpad proTecTion drapE iN redUcing rAdiaTion Exposure) Trial
Radiation Exposure
Primary: Operator Exposure (OE)/Dose Area Product (DAP) (uSv[Micro-Sieverts]/mGy[Milligray]*cm2) of the Proximal Operator — 6.41; 3.51 10,000 x uSv / mGy*cm^2
Phase 2 N=45 Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI
Adenomatous Polyp · Colorectal Cancer · Obesity
Primary: Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235) — 0.0228 weighted ratio of staining cells — p=> 0.773
Phase 2 N=141 Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention
Colorectal Adenomatous Polyps
Primary: Rectal Epithelial Cell Proliferation — 19.3; 20.3; 18.9; 16.8 percentage of cells positive
Phase 2 N=100 Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
Colon Cancer
Primary: Progression Free Survival — 38; 34; 6; 3 Participants
Phase 2 N=135 Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Rectal Carcinoma
Primary: Rate of Tumor Downstaging Compared With Historical Controls. — 64.4; 64.5 percentage of participants
N/A N=11 Familial Hyperlipidemia Family Registry
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants
Phase 2 N=154 Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rate — 56.47; 37.93 percentage of participants
Phase 2 N=66 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Rectal Cancer · Cancer of the Rectum · Colorectal Cancer
Primary: Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment…
Phase 2 N=47 RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
Colorectal Cancer
Primary: Progression Free Survival at Six Months — 87 percentage of participants
Phase 2 N=19 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
Gastrointestinal Cancer
Primary: Response Rate (RR) — 19 Participants
Phase 2 N=215 Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
Colorectal Cancer
Primary: Progression Free Survival — 5.8; 7.2; 7.8 Months
N/A N=35 Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma
Colorectal Adenoma · Risk Reduction
Primary: Change in Beta Catenin Expression — 100; 100; 100; 100 percentage of positive cells
Phase 2 N=70 Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months